New workshop aims to help chronic pain patients taper opioids safely

NCT ID NCT04902547

Completed Symptom relief Sponsor: University of Manitoba Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a one-day educational workshop for people with chronic non-cancer pain who take high doses of opioids. The workshop, led by a team of doctors, psychologists, and pharmacists, provided information on opioid risks and taught coping strategies. Researchers wanted to see if it changed attitudes toward reducing opioid use and helped participants lower their doses safely. 26 people took part in the completed study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Patient Education Workshop (behavioral intervention)
What this could lead to: If successful, this workshop could help people with chronic pain reduce their opioid doses safely, lowering risks of addiction and side effects.
What could go wrong: This is a small, completed study with only 26 participants. Results may not apply to everyone, and tapering opioids can be difficult for some.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERALGESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia Chronic Pain chronic pain syndrome Hyperalgesia opioid abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERALGESIA OPIOID USE OPIOIDS; HARMFUL USE PAIN, CHRONIC

Contacts and locations

Locations

ACCESS River East

Winnipeg, Manitoba, R3R 1K8, Canada
ACCESS Winnipeg West

Winnipeg, Manitoba, Canada
Health Sciences Centre Pain Clinic

Winnipeg, Manitoba, Canada
Pan Am Pain Clinic

Winnipeg, Manitoba, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.